Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma Equity Group ASOCSE:PEG +1.71% EV-to-EBIT is -13.40 as of Aug. 24, 2026. The stock has 3 warning signs investors should review. Among 377 Biotechnology companies, Pharma Equity Group AS ranks worse than 265251.72% on this metric.
Pharma Equity Group AS (OCSE:PEG) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Pharma Equity Group AS's Enterprise Value for the quarter that ended in Jun. 2026 was kr116.28 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pharma Equity Group AS's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was kr-8.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:PEG vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Pharma Equity Group AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Equity Group AS EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Equity Group AS's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Pharma Equity Group AS's EV-to-EBIT falls into.
Pharma Equity Group AS's current Enterprise Value is kr113.09 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pharma Equity Group AS's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was kr-8.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Equity Group AS (OCSE:PEG) has a EV-to-EBIT of -13.40 as of Aug. 24, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pharma Equity Group AS and its competitors. According to the industry distribution chart, Pharma Equity Group AS ranks #999999 out of 377 companies in the Biotechnology industry.
Is Pharma Equity Group AS's EV-to-EBIT too high?
Pharma Equity Group AS's current EV-to-EBIT is -13.40. Based on the distribution chart, Pharma Equity Group AS ranks #999999 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Pharma Equity Group AS's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Equity Group AS ranks #999999 out of 377 companies for EV-to-EBIT. This places Pharma Equity Group AS in the lower half of its industry. The industry median EV-to-EBIT is 16.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.02, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pharma Equity Group AS and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Equity Group AS's current EV-to-EBIT is -13.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Equity Group AS stock overvalued right now?
Pharma Equity Group AS (OCSE:PEG) has a current EV-to-EBIT of -13.40. The current EV-to-EBIT is -13.40. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Pharma Equity Group AS (OCSE:PEG), the current EV-to-EBIT is -13.40 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:PEG has been successfully added to your 
